TREM2 is the most druggable neurodegeneration target nobody has successfully hit yet

Microglial TREM2 signaling sits at the intersection of neuroinflammation and neurodegeneration. Variants that reduce TREM2 function increase Alzheimer's risk by 2-3x. The pathway is tractable—antibodies can modulate it. The problem is timing: we keep testing TREM2 activators in late-stage disease when microglia are already exhausted, not in the preclinical window when they might actually help.